Abbott has reported $11.5bn of worldwide sales for the fourth quarter (Q4) of 2021, representing growth of 7.2% on a reported basis and 7.7% on an organic basis.

During the quarter, the company’s global Covid-19 testing-related sales stood at $2.3bn, with sales for the full year at $7.7bn.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Abbott chairman and CEO Robert Ford said: “2021 was an outstanding year for Abbott. We achieved more than 40% EPS growth, exceeding the baseline EPS guidance we set at the beginning of last year and, importantly, continued to advance our new product pipeline across the portfolio.”

On a reported basis, the company’s worldwide diagnostics sales increased by 2.9%, while the organic basis increase was 3.3%.

Its Covid-19 testing-related sales across the world were $2.3bn, including $2.1bn of combined sales from rapid testing platforms Panbio, BinaxNOW and ID NOW. 

Excluding Covid-19 testing-related sales, in Molecular Diagnostics and Rapid Diagnostics, the company’s Q4 sales increased, on a reported basis, 24.1% and 9.7%, respectively.

Abbott’s Medical Devices business worldwide reported a 15.1% increase in sales on a reported basis and 15.9% on an organic basis.

The sales of FreeStyle Libre in Diabetes Care stood at $1bn in the fourth quarter, representing growth of 35.4% on a reported basis and 36% on an organic basis.

In 2021, the company received approval from the US Food and Drug Administration (FDA) for the Amplatzer Amulet Left Atrial Appendage Occluder and Portico with FlexNav transcatheter aortic valve replacement (TAVR) system.

Abbott’s latest generation TAVR system, Navitort, also received CE Mark.

This month, the company’s EnSite X EP System with EnSite Omnipolar Technology (OT) received US FDA clearance.